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ABSTRACT 
Objective: Kanamycin and capreomycin are the second lines injectable ant tuberculosis used in therapy regimen of multidrug resistance 
tuberculosis (MDR TB) in Indonesia. Both have effects on serum potassium levels and cause hypokalemia. The aim of this study is to compare and 
evaluate the effects of kanamycin and capreomycin on serum potassium levels of MDR TB patient.  
Methods: This was a retrospective and concurrent cohort study with intention-to-treat analysis on MDR TB patients during 2014 at Dr. Hasan 
Sadikin General Hospital Bandung, Indonesia. The patients were divided into two groups, one group received kanamycin regimen. Meanwhile, the 
other group received capreomycin regimen. Serum potassium level, the incidence of hypokalemia and the classification of its severity were 
compared monthly for five months of the therapy.  
Results: In the first two months, capreomycin significantly decreased serum potassium level stronger than kanamycin (2.95 mEq/l vs. 3.82 mEq/l, 
P<0.001 in the first month and 2.85 mEq/l vs. 3.81 mEq/l, P<0.001 in the second month). Before five months, the number of enabled patients to 
follow up decline which is caused by hypokalemia in capreomycin group was60.0% while in kanamycin group is 0.0%. 
Conclusion: Capreomycin has a stronger effect on decreasing serum potassium level compared to kanamycin, and it causes hypokalemia.  
Keywords: Second line Injectable Antituberculosis, Adverse Drug Reaction, Hypokalemia. 
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INTRODUCTION 
Multidrug resistance tuberculosis (MDR-TB), defined as an infection 
caused by Mycobacterium tuberculosis strain which is resistant to 
both isoniazid and rifampicin, still be a problem of eradication of 
tuberculosis (TB). World Health Organization (WHO) mentioned 
that in 2013 the prevalence of MDR TB was estimated 3.6% of new 
cases and 20.2% of the case handled in the wide world, whereas in 
Indonesia the number of MDR TB cases is 1.9% of new cases and 
12% of retreatment. Indonesia belongs to 27 countries with the 
highest MDR TB burdens [1]. 
MDR TB treatment uses, at least, four antituberculosis to which the 
Mycobacterium tuberculosis isolate is still sensitive including second-
line injectable antituberculosis. All second-line injectable drugs are 
bactericidal and related to several potentials of adverse effect. The 
second line injectable drug used in therapy regimen is kanamycin, 
capreomycin, and amikacin. Kanamycin is a second-line injectable 
drug used in standard regimen in Indonesia. On the other hand, a 
review article by Caminero [2] hypothesizes that capreomycin as the 
first choice of second-line injectable drug in MDR TB therapy.  
Kanamycin and capreomycin, classified as aminoglycoside group 
and cyclic polypeptide, have a disturbance effect on the electrolyte. 
It has been reported that the use of aminoglycoside and 
capreomycin causes the increase in renal electrolyte wasting, 
including potassium, magnesium, and calcium. Electrolyte 
disturbance particularly hypokalemia is related to several significant 
morbidities such as tetany, seizures, and cardiac arrhythmia [3]. 
Hypokalemia case undergone by MDR TB patients in the previous 
research was mentioned of 32% and 33.2% [4,5]. Therefore, serum 
potassium level is one of the most significant parameters in relation 
to the patient safety. 
The aim of the study is to compare and evaluate the effects of 
kanamycin and capreomycin on serum potassium level of MDR TB 
patients at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.  
MATERIALS AND METHODS 
This was a retrospective and concurrent cohort study with 
intention-to-treat analysis on MDR TB patients at MDR clinic Dr. 
Hasan Sadikin General Hospital Bandung, Indonesia. All adults’ 
pulmonary MDR-TB patients who start MDR-TB therapy with 
kanamycin standard regimen or capreomycin regimen during 2014 
were identified from the list of MDR clinic registration. Kanamycin 
standard regimen and capreomycin regimen differ only at second-
line injectable used which is combined with levofloxacin, 
ethionamide, cycloserine and pyrazinamide. The patients excluded 
such as un compliance patients, pregnant women, HIV-positive 
patients, patients with the history of second-line injectable 
antituberculosis treatment, and patients with renal impairment, 
alcohol or drug consumption and agents which affect serum 
potassium level such as insulin, angiotensin converting system 
(ACE) inhibitor, angiotensin II receptor blocker, non-steroidal anti-
inflammatory drug (NSAID), diuretic, amphotericin B, corticosteroid, 
β2-agonis, and potassium supplement). 
All patients involved in the study were divided into two groups, 
which were kanamycin regimen and capreomycin regimen. Initial 
demographic and clinical characteristics data of all patients were 
recorded such as age, gender, initial body weight, previous 
antituberculosis treatment history, comorbidities and smoking status. 
Initial serum potassium level before the treatment or baseline was 
also recorded. The patients were followed and monitored monthly for 
their serum potassium level for five months of the therapy. Each 
month the serum potassium level was recorded and analyzed 
statistically. The serum potassium level under 3.6 mEq/l was classified 
in regard to the severity of hypokalemia into mild(3.1-3.5 mEq/l), 
moderate(2.6-3.0 mEq/l), and severe (<2.5 mEq/l) [6]. 
The sample size of each group was calculated of 11 patients in each 
group. In the calculation, it was selected the power of 80%, the 
significance level (α) was 0.05 and based on the previous research it was 
assumed that the proportion of hypokalemia incidence in kanamycin 
group and capreomycin group was 10% and 68%, respectively [3]. 
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The consent of the regular data use was obtained from Department 
of Education and Training at Dr. Hasan Sadikin General Hospital 
Bandung. The ethical approval for the study was obtained from 
Research and Ethical Committee of Dr. Hasan Sadikin General 
Hospital Bandung. 
Statistical analysis  
Statistical analysis employed SPSS software version 22. Initial 
demographic and clinical characteristics were analyzed using 
independent sample t-test for continues data with normal 
distribution, Mann-Whitney test for continues data with normal 
distribution, and χ2
 
or Fisher’s exact test for categorical data. Mean 
serum potassium comparison levels each month with baseline value 
was analysed using paired t-test while the comparison between 
groups used independent sample t-test. The comparison of the 
number of hypokalemia incidence and the classification of its 
severity between groups were analyzed using Fisher’s exact test. 
P<0.05 was considered statistically significant difference. 
RESULTS 
Distribution of patients  
Total of 137 patients received MDR TB treatment during the study; 65 
patients were excluded (fig. 1) and the remaining 72 patients were 
involved in the study. 53 patients were as kanamycin standard regimen 
receivers, and 19 patients were as capreomycin regimen receivers. 
Fig. 1: Diagram of the study population included in the analysis 
 
Initial demographic and clinical characteristic of patients 
Initial demographic and clinical characteristic of each group are 
presented in table 1. Distribution of mean age, gender, mean initial 
body weight, the history of previous antituberculosis treatment, 
comorbidities, and smoking status were not significantly different 
from both groups. Antituberculosis was given based on the body 
weight per kg of the patient as shown in table 2. 
 
Table 1: Initial demographic and clinical characteristic 
 Kanamycin group (n = 53) n (%) Capreomycin group (n = 19) n (%) P-value 
Age (y) 36.17+11.88 a 37.32+10,15 0.710 
Gender    
Female 20 (37.7)  6 (31.6)  0.632 
Male 33 (62.3) 13 (68.4)  
History of Antituberculosis   0.501 
None 1 (1.9) 0 (0.0) 
Category I 15 (28.3)   5 (26.3) 
Categoy 2 1 (1.9) 2 (10.5)  
Category 1 and 2 36 (67.9)  12 (63.2)  
Comorbid    
0.204 None 49 (92.5) 16 (84.2) 
Diabetes 2 (3.8) 2 (10.5) 
Hypertension 0 (0.0) 1 (5.3) 
Chronic Hepatitis 2 (3.8) 0 (0.0) 
Initial Body Weight (kg) 44.20+7.78 a 47.0+11.61 0.417 
Smoking status    
>0.999 Ex-smoker 33 (62.3)   12 (63.2)  
Current smoker 1 (1.9)  0 (0.0)  




Table 2: Dose of Antituberculosis drug used 
 Dose (mg)/Body weight (kg)/d 
Body weight (kg) <33 kg 33-50 kg 51-70 kg >70 kg 
Kanamycin 15-20 750 1000 1000 
Capreomycin 15-20 750 1000 1000 
Ethionamid 15-20 500 750 1000 
Levofloxacin 7.5-10 750 750 1000 
Cycloserine 15-20 500 750 1000 
Pirazynamide 20-30 1500 1500 2000 
 
Table 3: Mean serum potassium level comparison each month with baseline value in kanamycin group 
 Time (m) 
Baseline 1 2 3 4 5 
Patients 53 53 48 44 41 38 
Serum potassium levels (mEq/l) 4.27+0.55 a 3.82+0.53 3.81+0.55 3.75+0.52 3.75+0.66 3.86+0.41 
Difference - 0.45 0.46 0.52 0.52 0.41 
P-value - <0.001* <0.001* <0.001* <0.001* <0.001* 
amean+SD 
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Table 4: Mean of serum potassium level comparison each month with baseline value in capreomycin group 
 Time (m) 
Baseline 1 2 3 4 5 
Patients 19 19 11 6 3 2 
Serum potassium levels (mEq/l) 4.06+0.47 a 2.95+0.72 2.85+0.65 3.18+0.91 3.75+1.46 3.86+1.06 
Difference - 1.11 1.21 0.88 0.31 0.20 
P-value - <0.001* <0.001* <0.001* <0.001* <0.001* 
a
 
Mean serum potassium level comparison  
Mean serum potassium level comparison at baseline and each month 
showed a significant decline in serum potassium level for the first 
month until the fifth month of therapy in both groups (table 3 and 
table 4). 
mean+SD 
Comparison between two groups (table 5), the average serum 
potassium level in capreomycin group was significantly lower than 
kanamycin group (2.95 mEq/lvs.3.82 mEq/l, P<0.001 in the first 
month and 2.85mEq/l vs. 3.81 mEq/l, P<0.001 in the second month). 
The incidence of hypokalemia (table 6) in the first two months in both 
groups also showed a significant difference. Capreomycin group 
showed higher incidence compared to kanamycin group (89.5% vs. 
28.3%, P<0.001 in the first month and 81.8 % vs. 29.2 %, P<0.001 in 
the second month). The severity of hypokalemia classification in the 
first month among capreomycin group was dominated by mild and 
moderate (36.8%), whereas kanamycin group was dominated by mild 
(22.6%). In the second month, capreomycin group was dominated by 
mild hypokalemia (54.5%), whereas kanamycin group was dominated 
by mild hypokalemia (20.8%). 
 
Table 5: Mean serum potassium level comparison each month between two groups 
Time 
(m) 
Group Patients Lowest serum potassium levels 
(mEq/l) 
























































Table 6: Incidence and severity of hypokalemia comparison between two groups 




Severity classification P-value 





























































Table 7: Declining number of enabled patients to follow up in two groups 
Reasons Kanamycin group 
(n = 53) n (%) 
Capreomycin group 
(n = 19) n (%) 
Related to hypokalemia 
Changed to kanamycin regimen and received potassium supplement 










Unrelated to hypokalemia 
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Declining number of patients 
Statistical analysis could not be performed in the next three months 
because the number of enabled patients to follow-up among 
capreomycin group decreased smaller than the limit of samples 
needed. The reason of the declining number of patients observed 
was the patients could not continue the treatment or did not meet 
the inclusion criteria anymore due to either related or unrelated to 
hypokalemia (table 7). The declining number of patients observed 
related to hypokalemia such as patients turned to use kanamycin 
regimen, to receive potassium supplement, and passed away due to 
arrhythmia. The number of patients declines related to hypokalemia 
was 60.0% patient in capreomycin group. 
DISCUSSION 
MDR-TB can be cured by an appropriate combination of 
antituberculosis agents. Several factors should be considered when 
determining the appropriate agents including the availability of the 
agents, the rationality of the drug use, the resistance profile of the 
patient, the history of drug use, the cost of therapy, and the 
possibility of toxic adverse events [2]. This study compared the 
effects of kanamycin and capreomycin in the use of MDR-TB therapy 
regimen on serum potassium level in order to evaluate the safety 
parameter related to the adverse effect.  
The current study showed declining serum potassium level in both 
groups since the first month of the therapy but the patients who 
received capreomycin significantly underwent declining serum 
potassium level greater than kanamycin receivers (2.95 mEq/l vs. 
3.82 mEq/l, P<0.001 in the first month and 2.85 mEq/l vs. 3.81 
mEq/l, p<0.001 in the second month). The incidence of hypokalemia 
was also higher in the patients receiving capreomycin than those 
receiving kanamycin (89.5% vs. 28.3%, P<0.001 in the first month 
and 81.8 %vs. 29.2 %, P<0.001 in the second month). The 
mechanism considered explaining this effect was stimulation of 
calcium-sensing receptor (CaSR) by both injectable drugs. CaSR is 
abasolateral receptor in the thick ascending limb of the loop of 
Henle, which is activated by aminoglycoside, polyvalent and cationic 
molecules. Capreomycin mentioned has a similar activity to an 
aminoglycoside. This stimulation could disrupt electrolyte transport 
via inhibition of four different pathways that involve Na+, K+,Cl-
symporter channel(NKCC2), renal outer medullary potassium 
channel (ROMK), Na+, K+-ATPase and/or paracellular diffusion. 
Inhibition of these transport mechanism leads to increased urinary 
excretion of Na+, K+, Mg+, and Ca2+
1. Katherine F, Annabel B, Anna D, Hannah MD, Dennis F, Inés G, 
et al. editors. Global tuberculosis report. France: WHO Library 
Cataloguing-in-Publication Data; 2013. 
and associated electrolyte 
disorders [7]. The stronger effect of capreomycin was assumed 
related to the number of amino group in its structure. It is known 
that capreomycin is antibiotic as a cyclic polypeptide which has 
many amino groups than kanamycin. The previous study reported 
that the potency order of several aminoglycoside was directly 
proportional with the number of amino group explaining the infirmity 
of kanamycin stimulation effect in CaSR having the least amino group 
compared to gentamicin, tobramycin, and neomycin (four, compared 
to five on gentamicin and tobramycin, and six on neomycin) [8]. The 
incidence of hypokalemia in capreomycin group caused several 
patients must change into kanamycin, unable continue the therapy 
without potassium supplement, and even died. This phenomenon 
showed that the use of capreomycin related to the higher 
hypokalemia potential which might cause the patients are not being 
able to continue the therapy and would increase the therapy cost. 
However, if the benefit of capreomycin use was highly required, then 
the monitoring of serum potassium level and preventive actions of 
hypokalemia must be conducted.  
CONCLUSION 
This study showed that the use of capreomycin in MDR-TB therapy 
regimen caused the declining of serum potassium level greater than 
the use of kanamycin significantly. Moreover, the incidence of 
hypokalemia was higher in the capreomycin group than kanamycin 
group caused several patients are not being able to continue the 
therapy without potassium supplement or must change into 
kanamycin. Monitoring serum potassium level and preventive actions 
of hypokalemia must be conducted in the use of capreomycin.  
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